Latest News

CanalLotus Biotech news and insights

Biohaven's Troriluzole Successfully Advances Past Interim Futility Analysis In Pivotal Phase 2/3 Alzheimer's Disease Study

NEW HAVEN, Conn., Dec. 6, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product c

Latest News Clinical News 2133
• Read All

Galera Therapeutics Announces Publication of GC4419 Data in the Journal of Clinical Oncology

MALVERN, Pa., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, prop

Latest News Clinical News 2107
• Read All

FDA Approves Caplyta (lumateperone) for the Treatment of Schizophrenia in Adults

NEW YORK, Dec. 23, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disord

Latest News NDA News 3769
• Read All

Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 5, 2019 -- Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company developing novel therapies for people with debilitating brain disorders, today reported

Latest News Clinical News 2243
• Read All

FDA Approves Ubrelvy (ubrogepant) for the Acute Treatment of Migraine

DUBLIN, Dec. 23, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for Ubrelvy (ubrogepant) for t

Latest News NDA News 2602
• Read All

American BriVision Initiates Phase II Part I Clinical Trial for ABV-1505 in Adult Attention-Deficit Hyperactivity Disorder (ADHD)

FREMONT, CA, Dec. 05, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- American BriVision (Holding) Corporation (OTCQB: ABVC) (the “Company”), a clinical stage biopharmaceutical company developing therape

Latest News Clinical News 2177
• Read All

FDA Approves Enhertu (fam-trastuzumab deruxtecan-nxki) for HER2-Positive Unresectable or Metastatic Breast Cancer Following Two or More Prior Anti-HER2 Based Regimens

20 December 2019 -- AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today announced that the US Food and Drug Administration (FDA) has approved Enhertu® (fam-trastuzumab deruxtecan-nx

Latest News NDA News 2696
• Read All

EIP Pharma Announces Presentation of Phase 2b Clinical Trial Results of Neflamapimod in Early-stage Alzheimer’s Disease at Clinical Trials in Alzheimer’s Disease (CTAD) Meeting

Boston, Mass., December 5, 2019 – EIP Pharma, Inc. (www.eippharma.com), a CNS-focused therapeutics company, today announced that the efficacy and safety data from the REVERSE-SD clinical study were pr

Latest News Clinical News 2018
• Read All

FDA Approves Dayvigo (lemborexant) for the Treatment of Insomnia in Adult Patients

December 23, 2019 -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) today announced that the U.S. Food and Drug Administration (FDA) approved the new drug application for its in-hous

Latest News NDA News 2540
• Read All

Regeneron Announces Positive Topline Phase 2 Data with Anti-C5 Antibody Pozelimab in Patients with a Rare Blood Disorder

TARRYTOWN, N.Y., Dec. 5, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced topline data from the pozelimab (REGN3918) Phase 2 clinical program in paroxysmal nocturnal

Latest News Clinical News 2374
• Read All

FDA Approves Conjupri (levamlodipine maleate) for the Treatment of Hypertension

Hong Kong, 20 December 2019 -- The board of directors (the “Board”) of CSPC Pharmaceutical Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that Conjup

Latest News NDA News 4995
• Read All

Allergan Announces Positive Phase 3 Achieve I Trial Results for Ubrogepant Published in the New England Journal of Medicine

DUBLIN, Dec. 4, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that positive results from ACHIEVE I (UBR-MD-01), a robust Phase 3 clinical trial evaluating the efficacy, safety and tole

Latest News Clinical News 2045
• Read All
News
Gloved hands holding a globe, global clinical trial drug sourcing
- CanalLotus Biotech -
Int'l Clinical Service Expert

We are the leader
Because of our professionism

WhatsApp Service QR code